We Just Had An Epiphany
Tag: Funanc1al Edge
Funds and Analysts Love BioMarin Pharmaceutical (BMRN), A Rare Combo of Value and Growth Fighting Also Rare Genetic Diseases. Should You?
BioMarin is that rare biotech: profits, pipeline, and price discipline. VOXZOGO grows, margins expand, and catalysts stack—at a surprisingly modest valuation.
Year-Old CEO Could Start Making an Impact: Can Teladoc (TDOC) Reboot Growth, Turn a Profit, and Send Its Stock Back to the Moon?
Teladoc Health is down 97% from ATH — but Citron says Livongo is booming, institutions are buying, and the CEO just hit his one-year mark. Bargain bin or value trap?
Target: Can the New CEO Finally Attract Bull’s Eye?
Target stock has lost 2/3 of its value since 2021. With a new CEO, strong dividends, and institutional support, is this retailer ready to bounce back?
Duolingo (DUOL): A Compelling Growth Investment and A Buy in Any Language?
Duolingo (DUOL) is flying high with 41% revenue growth, record profits, and a chess course attracting millions. Institutions can’t get enough. But is the stock a smart buy—or just owl-wardly expensive?
Peloton Interactive (PTON): Can This Fitness Unicorn Get Its Groove Back?
Peloton (PTON) is no longer just a bike company—it’s trying to pivot into a full wellness platform. Institutions are buying, shorts are circling, and the new CEO is bringing Apple/Ford cred. But can Peloton spin its way back to growth, or is this ride still too risky?